Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231550 | 0.83 | FFAR1 (0.47) | FFAR1PPARGPPARD | |
| SCHEMBL231413 | 0.75 | FFAR1 (0.42) | FFAR1PPARGPPARD | |
| SCHEMBL317962 | 0.74 | FFAR1 (0.45) | FFAR1PPARGPPARD | |
| SCHEMBL2742886 | 0.73 | FFAR1 (0.41) | FFAR1PPARGPPARD | |
| SCHEMBL2944400 | 0.72 | FFAR1 (0.43) | FFAR1PPARGPPARD | |
| SCHEMBL232572 | 0.72 | FFAR1 (0.50) | FFAR1PPARGSLC6A9 | |
| SCHEMBL231814 | 0.71 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL10064988 | 0.70 | FFAR1 (0.52) | FFAR1PPARGPPARD | |
| SCHEMBL231420 | 0.69 | FFAR1 (0.61) | FFAR1 | |
| SCHEMBL3013876 | 0.68 | FFAR1 (0.50) | FFAR1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | REN, PKD1, AKR1C3 | FFAR1 287/4885PPARG 313/4885PPARD 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.